Factorial Mendelian randomization of lipoprotein (a) lowering, low-density lipoprotein cholesterol lowering, and lifestyle improvements: joint associations with cardiovascular risk
International Journal of Epidemiology · 16.02.2025 · 54 (2)
DOI: 10.1093/ije/dyaf020 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Epidemiology, online erschienen am 10.03.2025. Verfasst von Lijuan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital and School of Public Health, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Lipoprotein(a), Cardiovascular Diseases, Life Style, Cholesterol, LDL. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, National Nature Science Foundation of China, American Heart Association Postdoctoral Fellowship.
Abstract (Originalsprache)
Background
High levels of lipoprotein(a) [Lp(a)] have been associated with an increased risk of cardiovascular disease (CVD); however, the effects of Lp(a)-lowering therapy in combination with low-density lipoprotein cholesterol (LDL-C)-lowering treatment or lifestyle improvements on CVD risk remain unexplored.
Methods
We conducted a factorial Mendelian randomization study among 385 917 participants in the UK Biobank. Separate genetic scores were constructed to proxy the effects of Lp(a) lowering, LDL-C lowering through different targets [HMG-CoA reductase, NPC1-like intracellular cholesterol transporter 1, proprotein convertase subtilisin/kexin Type 9, and low-density lipoprotein receptor (LDLR)], as well as improvements in body mass index (BMI), systolic blood pressure (SBP), and lifestyle factors (cigarette smoking, alcohol consumption, and physical activity).
Results
Genetically predicted lower Lp(a) levels were associated with a decreased risk of CVD and CVD-specific mortality. Per 50-mg/dl, the hazard ratio ranged from 0.73 [95% confidence interval (CI): 0.73, 0.73] for peripheral artery disease (PAD) to 0.95 (95% CI: 0.92, 0.99) for venous thromboembolism. In factorial analyses exploring combined exposure to low-level Lp(a) and low-level LDL-C, there was no consistent evidence for departure from an additive model for any outcome (Pinteraction > .05), with the exception of the analysis using the LDLR score and PAD (Pinteraction = .006). In factorial analyses exploring combination therapies integrating Lp(a) lowering with interventions on BMI, SBP, and lifestyle factors, there was no evidence for departure from an additive model in any analysis (Pinteraction > .05).
Conclusions
Our study suggests that Lp(a) lowering will have a similar magnitude for reducing cardiovascular events whether it is considered alone, or in conjunction with LDL-C reduction or lifestyle improvements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Affiliated Hospital and School of Public Health, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
- Sequoia Genetics, London, United Kingdom.
- MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.
- Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
ORCID-Profile: Lijuan Wang, Jing Sun, Dipender Gill, Stephen Burgess, Susanna C Larsson, Shuai Yuan
Förderung
- Wellcome Trust
- National Nature Science Foundation of China
- American Heart Association Postdoctoral Fellowship
Zitieren
APA
Wang, L., Jiang, F., Sun, J., Zhao, J., He, Y., Gill, D., Burgess, S., Larsson, S. C., Yuan, S., & Li, X. (2025). Factorial Mendelian randomization of lipoprotein (a) lowering, low-density lipoprotein cholesterol lowering, and lifestyle improvements: joint associations with cardiovascular risk. International Journal of Epidemiology, 54(2). https://doi.org/10.1093/ije/dyaf020
Vancouver
Wang L, Jiang F, Sun J, Zhao J, He Y, Gill D, et al. Factorial Mendelian randomization of lipoprotein (a) lowering, low-density lipoprotein cholesterol lowering, and lifestyle improvements: joint associations with cardiovascular risk. International Journal of Epidemiology. 2025;54(2). doi:10.1093/ije/dyaf020
BibTeX
@article{Wang2025,
author = {Wang, Lijuan and Jiang, Fangyuan and Sun, Jing and Zhao, Jianhui and He, Yazhou and Gill, Dipender and Burgess, Stephen and Larsson, Susanna C and Yuan, Shuai and Li, Xue},
title = {Factorial Mendelian randomization of lipoprotein (a) lowering, low-density lipoprotein cholesterol lowering, and lifestyle improvements: joint associations with cardiovascular risk},
journal = {International Journal of Epidemiology},
year = {2025},
volume = {54},
number = {2},
doi = {10.1093/ije/dyaf020}
}
EUVIMED